Migraine

The pediatric headache specialist at NYU Langone discussed adjusting management approaches to pediatric headache and the current state of research within the space.

Patients will be randomized to either 120-mg galcanezumab or 75-mg rimegepant and will be evaluated on the percentage of patients achieving a 50% reduction in monthly migraine headache days.

The treatment device from Theranica also demonstrated a positive impact on patients who experienced menstrual cramps or pelvic pain.

The pediatric headache specialist at NYU Langone discussed what physicians should be aware of related to the signs and symptoms associated with pediatric migraine.

The vice president of Medical Affairs in Migraine at Impel discussed the STOP 301 trial of intranasal DHE and how the safety profile offers a positive for patients who would use the agent on-demand.

At 2 hours after the start of the infusion, headache pain freedom was reported by 23.5% of patients receiving eptinezumab compared to 12% in the placebo group.

The vice president of Medical Affairs in Migraine at Impel discussed the gaps in care that novel dihydroergotamine formulations, such as INP104, might be able to fill for patients with migraine.

The director of the Headache Center of Southern California discussed research opportunities for layered treatment approaches in migraine.

The director of the Montefiore Headache Center discussed future aspirations and potential combinations that should be researched to treat patients with migraine.

The medical director of the Westport Headache Institute spoke to the role that devices can play in layered and variable treatment approaches, and how this better lends itself to offering personalized treatment to different individuals with migraine

The medical director of the Westport Headache Institute shared her insight into the use of the e-TNS device and the role of neuromodulation in migraine.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the role of clinicians in determining migraine treatment eligibility.

Lawrence Severt, MD, PhD, discussed the history of CGRP antagonists and what atogepant can potentially bring to the market pending approval.

A recent paper supported by several presentations at AAN 2021 elucidate areas of migraine care to improve.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the barriers to the use of preventive medicines.

Migraine with aura was associated with the risk of incident hypertension and no significant difference was observed between individuals with or without aura.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

The study will be based in West Haven, Connecticut, and enroll up to 100 veterans with the headache disorder.

Lawrence Severt, MD, PhD, discussed the results from the phase 3 ADVANCE trial of atogepant, and its effect on a number of patient-reported outcomes.

The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.

The director at AbbVie discussed a subgroup analysis of the phase 3 ADVANCE study of atogepant in patients with migraine and its benefit on patient-reported outcome measures.